WaveMan
WaveMan · Company
FOXO · Foxo Technologies Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

FOXO Foxo Technologies (FOXO) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Services-commercial physical & biological research · CIK 0001812360
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter

Foxo Technologies insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for FOXO TECHNOLOGIES INC. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Kr8 ai Inc.
SELL
2024-07-24 SECtraded 2024-07-22
1,300,000
$325.0K
+233.3%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • 2 other insiders sold within 30 days.
Insider activity: Insider Kr8 ai Inc. sold about $325.0K of FOXO on Jul 22, 2024, the largest insider sale at the company on our record; 2 other insiders sold within 30 days.
WHITE MARK BRIAN
Interim CEO
SELL
2024-07-24 SECtraded 2024-07-22
1,300,000
$325.0K
+233.3%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Feb 6, 2024.
  • 2 other insiders sold within 30 days.
Insider activity: Interim CEO WHITE MARK BRIAN sold about $325.0K of FOXO on Jul 22, 2024, the largest insider sale at the company on our record; 2 other insiders sold within 30 days.
WARD MARTIN CHRISTOPHER
Interim CFO
SELL
2024-07-24 SECtraded 2024-07-22
1,300,000
$325.0K
+233.3%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Feb 6, 2024.
  • 2 other insiders sold within 30 days.
Insider activity: Interim CFO WARD MARTIN CHRISTOPHER sold about $325.0K of FOXO on Jul 22, 2024, the largest insider sale at the company on our record; 2 other insiders sold within 30 days.
WARD MARTIN CHRISTOPHER
Interim CFO
SELL
2024-02-07 SECtraded 2024-02-06
250,000
$105.0K
+233.3%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • 1 other insider sold within 30 days.
Insider activity: Interim CFO WARD MARTIN CHRISTOPHER sold about $105.0K of FOXO on Feb 6, 2024, the largest insider sale at the company on our record; 1 other insider sold within 30 days.
WHITE MARK BRIAN
Interim CEO
SELL
2024-02-07 SECtraded 2024-02-06
250,000
$105.0K
+233.3%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • 1 other insider sold within 30 days.
Insider activity: Interim CEO WHITE MARK BRIAN sold about $105.0K of FOXO on Feb 6, 2024, the largest insider sale at the company on our record; 1 other insider sold within 30 days.
6 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 1 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
+304.0% year over year
more than 91% of Pharma & Biotech
Margin
-75.9% net margin
below 54% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
0.4% of the float short (float per yahoo 2026-10-26) · 1.0 days to cover · settled 2026-09-30
below 82% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch FOXO

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+233.3%12M
+0%+133%+267%+400%2026-072026-082026-082026-092026-092026-102026-10
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns FOXO: institutional holders (13F)

13F holdings, latest reported quarter
SEC 13F
No reported 13F holders

No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.

Congress trades in FOXO

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

FOXO planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
Each figure here is a federal filing, dated the day it went public, so you can test what was knowable then.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

FOXO financials

Revenue growth
+304.0%
XBRL, annual
Net margin
-75.9%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$17.9M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-25.8%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
2.95x
long-term debt only, 2022-09-30 (45 months older than the period end); equity 2026-06-30
Cash flow to debt
-0.15x
TTM operating cash flow over long-term debt only, 2022-09-30 (45 months older than the period end)
Return on equity
-62.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-9.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-7.8%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Enterprise value
$3.0M
market value at close 2026-10-26 on 2026-08-11 shares, plus long-term debt only, 2022-09-30 (45 months older than the period end), minus cash 2026-06-30
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$16.4M$4.1M$145.3K$511.0K
Gross profitn/an/a$13.0K$167.0K
Operating income-$10.3M-$7.8M-$22.2M-$40.2M
Net income-$12.4M-$12.4M-$26.5M-$95.3M
Operating cash flow-$3.9M-$2.8M-$6.6M-$23.8M
Cash$207.5K$68.3K$38.1K$5.5M
SEC XBRL, fiscal years, as known on 2026-10-28

FOXO Stock Sonar score 4/7 axes

Find similar shapesCompare

FOXO ranks highest on growth (91st percentile) and profitability (67th), and lowest on financial health (36th), among Pharma & Biotech peers.

Profitability
67
Inputs
  • Return on equity-62.5% · 46 pct, sector of 545
  • Return on assets-9.6% · 75 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-7.8% · 80 pct, sector of 576
Financial health
36
Inputs
  • Debt to equity2.95x · 6 pct, sector of 352
  • Cash flow to debt-0.15x · 65 pct, sector of 371
Growth
91
Inputs
  • Revenue growth, YoY+304.0% · 91 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Risk and compliance
47
Inputs
  • Short interest, % of float+0.4% · 88 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+29.8% · 7 pct, sector of 511
3 not measured: Insider conviction, Institutional and government, US patents
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies